MCDERMOTT WILL & EMERY REPRESENTS INHIBIKASE THERAPEUTICS IN ITS $4M REGISTERED DIRECT OFFERING
July 19, 2024
July 19, 2024
CHICAGO, Illinois, July 19 -- McDermott Will and Emery, a law firm, issued the following news release:
International law firm McDermott Will & Emery represented Inhibikase Therapeutics, Inc. (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, in entering into a securities purchase agreement wit . . .
International law firm McDermott Will & Emery represented Inhibikase Therapeutics, Inc. (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, in entering into a securities purchase agreement wit . . .